The key role of CD40 ligand in overcoming tumor-induced dendritic cell dysfunction

Breast Cancer Research : BCR
Alberto Pinzon-CharryJosé Alejandro López

Abstract

Overcoming dendritic cell (DC) dysfunction is a prerequisite for successful active immunotherapy against breast cancer. CD40 ligand (CD40L), a key molecule in the interface between T-lymphocytes and DCs, seems to be instrumental in achieving that goal. Commenting on our data that CD40L protects circulating DCs from apoptosis induced by breast tumor products, Lenahan and Avigan highlighted the potential of CD40L for immunotherapy. We expand on that argument by pointing to additional findings that CD40L not only rescues genuine DCs but also functionally improves populations of immature antigen-presenting cells that fill the DC compartment in patients with breast cancer.

References

Mar 2, 1999·The Journal of Experimental Medicine·M CellaA Lanzavecchia
Jun 3, 2000·Annual Review of Immunology·J BanchereauK Palucka
Jun 8, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·P TerheydenJ C Becker
Dec 29, 2000·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·A LisoR Levy
Jan 24, 2004·Cancer Immunology, Immunotherapy : CII·Sukchai SatthapornOleg Eremin
May 4, 2004·Nature Medicine·Carl G FigdorCornelis J M Melief
Nov 10, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Susanne BeckebaumVito R Cicinnati
Sep 22, 2005·Immunology and Cell Biology·Alberto Pinzon-CharryJ Alejandro López
Dec 16, 2005·Neoplasia : an International Journal for Oncology Research·Alberto Pinzon-CharryJosé Alejandro López
Dec 16, 2005·Neoplasia : an International Journal for Oncology Research·Alberto Pinzon-CharryJosé Alejandro López
Jan 19, 2006·Breast Cancer Research : BCR·Alberto Pinzon-CharryJ Alejandro López
Feb 14, 2006·Breast Cancer Research : BCR·Corrine Lenahan, David Avigan

❮ Previous
Next ❯

Citations

Jan 30, 2013·Chinese Journal of Cancer Research = Chung-kuo Yen Cheng Yen Chiu·Xiao-Lin LinJun Ren
Feb 1, 2007·Frontiers of Medicine in China·Qingwen Xu, Weifeng Chen
Apr 29, 2008·Annals of Surgery·D Kay BlanchardRichard M Elledge
Jul 14, 2009·Journal of Translational Medicine·Ramon KanenoMichael R Shurin
Feb 14, 2006·Breast Cancer Research : BCR·Corrine Lenahan, David Avigan
Aug 2, 2008·Breast Cancer Research : BCR·Brian J MorrisonJ Alejandro Lopez
Feb 22, 2007·Journal of Leukocyte Biology·Anne Sophie Hatzfeld-CharbonnierPhilippe Marchetti
Jun 10, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Maria A Gonzalez-CarmonaVolker Schmitz
Oct 10, 2007·British Journal of Cancer·A Pinzon-CharryJ A López
Aug 15, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Aleksandra KornilukVioletta Dymicka-Piekarska
Aug 29, 2012·International Journal of Cancer. Journal International Du Cancer·Mariana S Nars, Ramon Kaneno
Mar 23, 2011·Molecular Biology Reports·Rui LiXue-Guang Zhang
Aug 27, 2016·Immunology·Frederick S VarnChao Cheng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.